Voyager Therapeutics Discloses Updated Six-Month GLP Non-Human Primate Toxicology Data for VY1706 (Tau-Targeted Blood-Brain-Barrier-Crossing AAV Gene Therapy) at AAIC 2026 Monday July 13: Single Intravenous Dose Delivered Sustained Tau Protein Reduction Up to 75% in Key Brain Regions of NHPs Through Six Months (Extending the Prior 64% Reduction at Three Months), With No Adverse Clinical Pathology, No AAV Liver Transaminase Elevations, Stable Plasma Neurofilament Levels, and No Cellular Immune Activations; Initiation of Clinical Trial in Adults With Early Alzheimer's Disease Remains Expected in Second Half of 2026 Following FDA IND Clearance
Voyager Therapeutics (NASDAQ: VYGR) presented six-month Good Laboratory Practice (GLP) toxicology data for VY1706, its investigational blood-brain-barrier-crossing AAV gene therapy targeting tau for Alzheimer's disease, in a Developing Topics late-breaking poster at AAIC 2026 in London on Monday July 13, 2026. The updated six-month data extends the prior three-month timepoint (64% reduction reported earlier this month): a single intravenous dose delivered sustained tau protein reduction up to 75% in key brain regions of non-human primates over six months. VY1706 was well tolerated with no adverse clinical pathology and no histopathological findings up to the highest dose tested. Notably, the program showed none of the typical AAV liver transaminase elevations at any dose level throughout six months, plasma neurofilament levels remained generally stable with no dose-related increases, and there were no cellular immune activations. Voyager received FDA Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early Alzheimer's disease with dosing expected in the second half of 2026.